Suppr超能文献

蒿甲醚单药口服及与甲氟喹序贯联合治疗急性非复杂性恶性疟的开放随机试验

Open randomized trial of oral artemether alone and a sequential combination with mefloquine for acute uncomplicated falciparum malaria.

作者信息

Looareesuwan S, Wilairatana P, Viravan C, Vanijanonta S, Pitisuttithum P, Kyle D E

机构信息

Department of Clinical Tropical Medicine, Mahidol University, Bangkok, Thailand.

出版信息

Am J Trop Med Hyg. 1997 Jun;56(6):613-7. doi: 10.4269/ajtmh.1997.56.613.

Abstract

One hundred fifty-one patients with acute uncomplicated falciparum malaria were enrolled in a randomized, open-label study of oral artemether given alone for five or seven days or a sequential treatment of oral artemether followed by mefloquine. Forty patients received oral artemether, 100 mg initially, then 50 mg every 12 hr for a total dose of 500 mg over a five-day period: Group I. Fifty-eight patients received oral artemether, 100 mg initially, then 50 mg every 12 hr for a total dose of 750 mg over a seven-day period: Group II. Fifty-three patients received oral artemether, 200 mg every 8 hr for a total dose of 600 mg, followed 8 hr later with mefloquine (1,250 mg divided into two doses given 6 hr apart: Group III. All patients were admitted to the hospital for 28 days to exclude reinfection and 131 patients remained through the 28-day follow-up. Only two, nine, and nine patients in Groups I, II, and III, respectively, left the hospital prior to study completion for reasons unrelated to their treatment. Cure rates for the three groups were 74% (28 of 38) for Group I, 98% (48 of 49) for Group II, and 98% (43 of 44) for Group III. Mean fever and parasite clearance times were not significantly different (32.8, 27.5, and 31.4 hr for fever clearance times and 40.2, 40.6, and 36.7 hr for parasite clearance times of Groups I, II, and III, respectively) nor were any adverse effects seen. In vitro drug susceptibility testing of admission and recrudescent parasite isolates was conducted for 10 patients. These data showed no decreased response to artemether or dihydroartemisinin in recrudescent isolates when compared with admission isolates. The results of this study suggest that sequential treatment for two days with oral artemether (600 mg) followed by mefloquine (1,250 mg) is effective and well-tolerated in patients with acute uncomplicated falciparum malaria and may be an alternative treatment for multidrug-resistant falciparum malaria, particularly useful for treating patients in rural areas where the period of admission to the hospital should be as short as possible. A seven-day regimen of artemether alone (750 mg) is also very effective, yet requires prolonged administration of drug after malaria symptoms disappear.

摘要

151例急性非复杂性恶性疟患者参与了一项随机、开放标签研究,该研究比较单独口服蒿甲醚5天或7天,以及蒿甲醚序贯甲氟喹的治疗效果。40例患者接受口服蒿甲醚,初始剂量100mg,随后每12小时50mg,5天总剂量500mg:第一组。58例患者接受口服蒿甲醚,初始剂量100mg,随后每12小时50mg,7天总剂量750mg:第二组。53例患者接受口服蒿甲醚,每8小时200mg,总剂量600mg,8小时后给予甲氟喹(1250mg分两剂,间隔6小时给药):第三组。所有患者住院28天以排除再感染,131例患者完成了28天的随访。只有第一组、第二组和第三组分别有2例、9例和9例患者因与治疗无关的原因在研究完成前出院。三组的治愈率分别为第一组74%(38例中的28例)、第二组98%(49例中的48例)和第三组98%(44例中的43例)。平均退热时间和寄生虫清除时间无显著差异(第一组、第二组和第三组的退热时间分别为32.8小时、27.5小时和31.4小时,寄生虫清除时间分别为40.2小时、40.6小时和36.7小时),也未观察到任何不良反应。对10例患者的入院和复发病原虫分离株进行了体外药敏试验。这些数据表明,与入院分离株相比,复发病原虫分离株对蒿甲醚或双氢青蒿素的反应没有降低。本研究结果表明,对于急性非复杂性恶性疟患者,口服蒿甲醚(600mg)序贯甲氟喹(1250mg)治疗两天有效且耐受性良好,可能是多重耐药恶性疟的替代治疗方法,尤其适用于农村地区需要尽可能缩短住院时间的患者。单独使用蒿甲醚的7天疗程(750mg)也非常有效,但在疟疾症状消失后需要延长药物给药时间。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验